Status:
UNKNOWN
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborating Sponsors:
Innovent Biologics, Inc.
Conditions:
Unresectable Gastric Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
This study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (SOX or PS) in the clinical practic...
Eligibility Criteria
Inclusion
- Ages: 18-75 Years (concluding 18 and 75 Years)
- Pathologically confirmed gastric/gastroesophageal junction adenocarcinoma
- Unresectable, locally advanced or limited distant metastasis of IV gastric cancer(AJCC 8th)
- Meets only ≤2 of the following conditions: highly locally advanced (T4b), or extensive or bulcky lymph nodes; Para-aortic lymph node metastasis(mainly 16A2/B1 region); limited liver metastasis(H1); limited Peritoneal metastasis(CY1, P1), with or without ovarian metastasis(Kukernburg tumor);
- Untreated(e.g. radiotherapy, chemotherapy, target therapy, immunotherapy, et al.)
- At least 1 measurable lesion by RECIST v1.1 criteria
- ECOG PS: 0-2
- Received sintilimab combined with chemotherapy(SOX or PS) at least 1 cycle
Exclusion
- Known Her2 positive
- Patients with incomplete data or other factors affecting the judgment of efficacy and safety
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05385809
Start Date
June 1 2022
End Date
December 31 2023
Last Update
November 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022